A subsidiary of Merck & Co. Inc., of Whitehouse Station, N.J., and Eli Lilly and Co., of Indianapolis, formed an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials.